NCT02507648View on ClinicalTrials.gov

A Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

May 31, 2013

Conditions
Healthy
Interventions
DRUG

Oseltamivir

1 tablet contains 75 mg oseltamivir

DRUG

Tamiflu®

1 tablet contains 75 mg oseltamivir

Trial Locations (1)

Unknown

Genuine Research Center GRC, Cairo

All Listed Sponsors
collaborator

Pharmacare PLC, Palestine

UNKNOWN

lead

Genuine Research Center, Egypt

INDUSTRY

NCT02507648 - A Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland) | Biotech Hunter | Biotech Hunter